ACRS vs. ETON, CLSD, ORMP, ANIX, MIST, ADAG, BYSI, PRPH, ONCY, and IOBT
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Eton Pharmaceuticals (ETON), Clearside Biomedical (CLSD), Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Adagene (ADAG), BeyondSpring (BYSI), ProPhase Labs (PRPH), Oncolytics Biotech (ONCY), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Eton Pharmaceuticals (NASDAQ:ETON) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Eton Pharmaceuticals has a net margin of -2.96% compared to Eton Pharmaceuticals' net margin of -283.15%. Aclaris Therapeutics' return on equity of -6.21% beat Eton Pharmaceuticals' return on equity.
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 13.2% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Aclaris Therapeutics received 293 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 66.96% of users gave Aclaris Therapeutics an outperform vote while only 62.22% of users gave Eton Pharmaceuticals an outperform vote.
Eton Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 141.94%. Aclaris Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 1,723.77%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Eton Pharmaceuticals.
Eton Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
Eton Pharmaceuticals has higher revenue and earnings than Aclaris Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aclaris Therapeutics had 5 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 10 mentions for Aclaris Therapeutics and 5 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.48 beat Aclaris Therapeutics' score of 0.17 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Summary
Eton Pharmaceuticals beats Aclaris Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
